Página principal > Resultados de la búsqueda: Havrdova, Eva K.
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 3 registros encontrados en 0.01 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
14 p, 1.0 MB Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis : 6-year results from the SELECTED open-label extension study / Gold, Ralf (Ruhr-University Bochum) ; Radue, Ernst-Wilhem (University Hospital Basel (Basilea, Suïssa)) ; Giovannoni, Gavin (Queen Mary University of London) ; Selmaj, Krzysztof. (University of Warmia and Mazury) ; Havrdova, Eva Kubala (Charles University) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Stefoski, Dusan (Rush University Medical Center) ; Sprenger, Till (DKD Helios Klinik Wiesbaden) ; Robinson, Randy R. (AbbVie Inc.) ; Fam, Sami (Biogen) ; Smith, Jonathan (Biogen) ; Chalkias, Spyros (Biogen) ; Giannattasio, Giorgio (Biogen) ; Lima, Gabriel (Biogen) ; Castro-Borrero, Wanda (Biogen) ; Universitat Autònoma de Barcelona
Objective: SELECTED, an open-label extension study, evaluated daclizumab beta treatment for up to 6 years in participants with relapsing multiple sclerosis who completed the randomized SELECT/SELECTION studies. [...]
2020 - 10.1007/s00415-020-09835-y
Journal of Neurology, Vol. 267 Núm. 10 (january 2020) , p. 2851-2864  
Registro completo - Creative Commons
2.
6 p, 852.9 KB Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis / Brochet, Bruno (University of Bordeaux) ; Hupperts, Raymond (Maastricht University Medical Center) ; Langdon, Dawn (Royal Holloway University of London) ; Solari, Alessandra (Fondazione IRCCS Istituto Neurologico Carlo Besta) ; Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ; Lechner-Scott, Jeannette (Newcastle University. John Hunter Hospital) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Selmaj, Krzysztof (Center for Neurology, Lodz, Poland) ; Valis, Martin (Charles University and University Hospital, Czech Republic) ; Rejdak, Konrad (Medical University of Lublin) ; Havrdova, Eva K. (Charles University, Prague, Czech Republic) ; Patti, Francesco (University of Catania) ; Alexandri, Nektaria (Merck Healthcare KGaA, Darmstadt, Germany) ; Nolting, Axel (Merck Healthcare KGaA, Darmstadt, Germany) ; Keller, Birgit (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona. Departament de Medicina
Background Multiple sclerosis (MS) is a chronic disabling disease that is associated with negative effects on health-related quality of life (HRQoL) due to reduced physical and psychosocial functioning. [...]
2022 - 10.1016/j.msard.2021.103385
Multiple Sclerosis and Related Disorders, Vol. 57 (2022) , p. 103385  
Registro completo - Creative Commons
3.
8 p, 976.6 KB Efficacy and safety of ozanimod in multiple sclerosis : Dose-blinded extension of a randomized phase II study / Cohen, Jeffrey A. (Mellen Center for MS Treatment and Research, Cleveland Clin) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Arnold, Douglas Lorne (McGill University, Montreal) ; Bar-Or, Amit (University of Pennsylvania. Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology) ; Selmaj, Krzysztof W. (Center for Neurology, Łódź, Poland) ; Steinman, Lawrence (Stanford University Medical Center) ; Havrdová, Eva K. (Charles University. Department of Neurology and Center for Clinical Neuroscience) ; Cree, Bruce A. C. (University of California. UCSF Weill Institute for Neurosciences) ; Montalbán, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina) ; Hartung, Hans-Peter (Heinrich Heine University. Department of Neurology) ; Huang, Vivian (Celgene Corporation, San Diego, CA) ; Frohna, Paul (Celgene Corporation, San Diego, CA) ; Skolnick, Brett E. (Celgene Corporation, San Diego, CA) ; Kappos, Ludwig (University Hospital Basel (Basilea, Suïssa))
Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing multiple sclerosis were randomized (1:1:1) to once-daily ozanimod hydrochloride (0. [...]
2018 - 10.1177/1352458518789884
Multiple sclerosis, Vol. 25 (july 2018) , p. 1255-1262  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Havrdova, E
1 Havrdova, E.K.
1 Havrdova, Eva
1 Havrdova, Eva
1 Havrdova, Eva Kubala
1 Havrdová, E.K.
2 Havrdová, Eva K.
1 Havrdová, Eva Kubala
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos